lifestyle.imone2015.com

Author: IRLAB Therapeutics

Nomination Committee’s proposal to the Board of Directors for IRLAB Therapeutics’ Annual General Meeting 2026

April 17, 2026
IRLAB to Present at Redeye Healthcare Day 2026

April 9, 2026
IRLAB to Present Clinical and Preclinical Data at The AD/PD(TM) 2026 – 20th International Conference on Alzheimer’s & Parkinson’s Diseases

March 17, 2026
IRLAB Participates in Life Science Day in Gothenburg on March 4, 2026

March 2, 2026
IRLAB Secures Milestone Payment for First Patient Dosed in Phase Ib Study with IRL757 in Parkinson’s Disease

February 26, 2026
IRLAB Publishes Full-Year Report for The Period January – December 2025

February 25, 2026
IRLAB has Received Scientific Advisory Board Confirmation on Next Steps for Pirepemat

February 22, 2026
IRLAB: Invitation to the Year-End Report 2025 Presentation and Webcast

February 21, 2026
IRLAB Enters Collaboration Agreement with Danish Biotech Company Biomia ApS Applying the Integrative Screening Process (ISP)

January 19, 2026
IRLAB Receives Approval for a Phase Ib Study with IRL757 in Parkinson’s Disease

December 23, 2025